IMTX Stock Forecast: Immatics NV Price Predictions for 2026-2027
The 9 Wall Street analysts covering Immatics NV hold a median 12-month price target of $15 — +159.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 22 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Immatics NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (74): The share price has been relatively steady.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IMTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IMTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +159.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | Stifel | Initiates | Buy | $15 |
| 19 May 2026 | Chardan Capital | Maintains | Buy | $25 |
| 28 Apr 2026 | TD Cowen | Initiates | Buy | — |
| 16 Mar 2026 | Jefferies | Assumes | Buy | $18 |
| 24 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 19 Nov 2025 | Mizuho | Maintains | Outperform | — |
| 18 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 18 Sept 2025 | Guggenheim | Initiates | Buy | — |
| 28 May 2025 | Deutsche Bank | Initiates | Buy | — |
| 1 Apr 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 19 Nov 2024 | B of A Securities | Maintains | Buy | — |
| 7 Oct 2024 | Piper Sandler | Initiates | Overweight | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 5 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 16 May 2024 | Mizuho | Maintains | Buy | — |
| 2 Nov 2023 | Cantor Fitzgerald | Initiates | Overweight | — |
| 31 Mar 2023 | Mizuho | Initiates | Buy | — |
| 23 Mar 2023 | Chardan Capital | Maintains | Buy | — |
| 10 Aug 2022 | Chardan Capital | Maintains | Buy | — |
| 3 June 2022 | SVB Leerink | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IMTX.
This page is one stock. Monday covers all of them.
IMTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IMTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Immatics NV returned −42.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IMTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 20.3×
- Price / book
- 1.8×
- EV / EBITDA
- —
Cheaper than 8% of US stocks
Cheaper than 48% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −54.3%
- Return on assets
- −28.9%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Immatics NV has a market value of $906.0M and an enterprise value of $491.5M.
Revenue in the twelve months to 30 June 2026: $41.7M. The latest quarter grew 93.0% year on year.
Net income over the same four quarters: −$206.5M, a −495.3% net margin.
Free cash flow in the twelve months to 30 June 2026: −$209.6M.
Immatics NV employs 721 people — $58K of revenue per employee.
Data provided by Twelve Data
IMTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IMTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Immatics NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IMTX
What is the IMTX stock price forecast for 2026-2027?
The 9 Wall Street analysts covering Immatics NV have a median 12-month price target of $15, with estimates ranging from $12 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IMTX stock a buy right now?
Of the 9 analysts covering Immatics NV, 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immatics NV 22 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IMTX?
As at 21 Nov 2026, Immatics NV ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (74 of 100).
Will IMTX stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +159.5% from the last close, and Ticker Nerd's factor model ranks Immatics NV 22 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IMTX stock forecast for 2030?
No analyst covering Immatics NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $21 over the next 12 months.
How has IMTX stock performed over the past year?
Immatics NV returned -42.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Immatics NV do?
Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell receptor-based immunotherapies for cancer. The company develops T-cell redirecting treatments designed to help the immune system recognize and attack solid tumors, with programs spanning adoptive cell therapies and TCR bispecifics.
About Immatics NV.
Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell receptor-based immunotherapies for cancer. The company develops T-cell redirecting treatments designed to help the immune system recognize and attack solid tumors, with programs spanning adoptive cell therapies and TCR bispecifics. Its current work centers on PRAME-targeted immunotherapy, a cancer-associated target used across multiple oncology applications. Immatics N.V. operates as a research-driven oncology company with a pipeline built around precision immunotherapy platforms and collaborations that support the development of next-generation cancer treatments. Headquartered in Tübingen, Germany, the company serves the broader biopharmaceutical market through its focus on novel therapies for patients with difficult-to-treat cancers.
CEO Dr. Harpreet Singh Ph.D. · 721 employees · Germany · https://www.immatics.com